MedTrace Logo

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

NCT00457678 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-08-23

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Visudyne

DRUG

Lucentis

DRUG

Dexamethasone

Sponsors & Collaborators

  • QLT Inc.

    collaborator INDUSTRY

  • Vitreous -Retina- Macula Consultants of New York

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-12-04
Completion
2007-12-04

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457678 on ClinicalTrials.gov